Dr Ivona Baricevic-Jones

Dr Ivona Baricevic-Jones

Contact details:



BSc (Hons) in Biochemistry:  University of Belgrade, Serbia, 1995

MSc (Hons) in Biochemistry: University of Belgrade, Serbia, 1999

PhD in Biochemistry:  University of Belgrade, Serbia, 2004

Present appointments:

  • Donal O’Donoghue Renal Research Centre (DRRC) Manager, Research & Innovation, Northern Care Alliance NHS Foundation Trust: October 2022 – present
  • Member of the International Advisory Board for Transformation plan implementation in the Institute of Application of Nuclear Energy in Belgrade, University of Belgrade, Serbia: September 2022 – present.

Previous appointments:

  • Post-doctoral fellow, Institute for the Application of Nuclear Energy, University of Belgrade: February 2004 – October 2009
  • Research Associate, Institute of Cancer Sciences, University of Manchester: November 2009 – September 2014
  • Reacta-Biotech Ltd Data Room Project Manager, Manchester Institute for Biotechnology, University of Manchester: October 2014 – April 2015
  • Laboratory Operations Manager/Projects Coordinator, Manchester Institute for Biotechnology, University of Manchester: May 2015 – February 2017
  • Project Manager, Manchester Institute of Biotechnology, University of Manchester: March 2017 – April 2017
  • Laboratory Manager, Stoller Biomarker Discovery Centre, University of Manchester: May 2017 – December 2018
  • Scientific Project Manager, Stoller Biomarker Discovery Centre, University of Manchester: January 2019 – September 2022

Research experience:

  • 2009 to 2014 (Post-doctoral research in the laboratory):

HOMER project: Development of HPV genOtyping as a predictive bioMarkEr of chemo-radiotherapy response in patients with Rectal Cancer.

ENHANCE project: DEep GeNotyping of HPV in ANal CancEr. HPV genotyping in a large contemporary UK anal cancer series using high-sensitivity detection method (multiplex PCR) and to determine SNPs in HPV 16.

INSULIN X10 project: Characterisation of mitogenic effects and signalling pathways activated by insulin, insulin analogue X10 and IGF-I in colon cancer cells.

  • 2014 to 2017 (Project Research Coordinator):

Lead researcher and communicator on the FP7 EU iFAAM project, that was led by the University of Manchester. Principal scientist in the Molecular Allergology Group ensuring delivery of scientific multi-project results for Work Packages and Modules. Organiser of annual report and submission of all deliverables via the EU portal.

Scientific review of research activity of all 43 iFAAM partners and preparation of final reports to ensure they have an appropriate technical content, are consistent with the iFAAM description of work and provision of a record of deviations and corrective actions undertaken.

  • 2017 to 2022 (Scientific Project Manager):

Initiate, lead and manage all scientific research projects with academic partners and life science technology companies to ensure success and wide-reaching dissemination of results; responsible for business development, financial management, communication through various channels with clients/collaborators, day-to-day supervision of Research Technicians and compliance with University’s health and safety regulations.

Publications and patents (last 5 years):



Su KYC, Reynolds JA, Reed R, Da Silva R, Kelsall J, Baricevic-Jones I, Lee D, Whetton AD, Geifman N, McHugh N, Bruce IN; the MASTERPLANS and BILAG-BR consortia, Proteomic analysis identifies subgroups of patients with active systemic lupus erythematosus. Clin Proteomics 2023 Jul 29;20(1):29.

Ramirez Medina CA, Ali I, Baricevic-Jones I, Odudu A, Saleem MA, Whetton AD, Kalra PA, Geifman N, Proteomic signature associated with chronic kidney disease (CKD) progression identified by data-independent acquisition mass spectrometry. Clin. Proteomics 2023 Apr 20;20(1):19.

Njoku K, Pierce A, Geary B, Campbell AE, Kelsall J, Reed R, Armit A, Da Sylva R, Zhang L, Agnew H, Baricevic-Jones I, Chiasserini D, Whetton AD, Crosbie EJ (2023) Quantitative SWATH-based proteomic profiling of urine for the identification of endometrial cancer biomarkers in symptomatic women. Br. J. Cancer. 2023 Feb 17. Doi: 10.1038/s41416-022-02139-0.


Spick M, Campbell A, Baricevic-Jones I, Von Gerichten J, Lewis Holly-May, Frampas CF, Longman K, Stewart A, Dunn-Walters D, Skene DJ, Geifman N, Whetton AD, Bailey MJ (2022) Multi-omics reveals mechanisms of partial modulation of COVID-19 Dysregulation by Glucocorticoid Treatment. Int. J. Mol. Scie. 2022; 23(20)12079.

Chatzimavridou-Grigoriadou V, Barraclough LH, Baricevic-Jones I, Bristow RG, Eden M, Haslett K, Johnson K, Kochhar R, Merchant Z, Moore J, O’Connell S, Taylor S, Westwood T, Whetton AD, Yorke J, Claire E Higham CE. RadBone: Bone Toxicity following Pelvic Radiotherapy. A prospective randomised controlled feasibility study evaluating a musculoskeletal health package in women with gynaecological cancers undergoing pelvic radiotherapy. BMJ Open 2022; 12(6):e056600.


Fachim HA, Iqbal Z, Gibson JM, Baricevic-Jones I, Campbell AE, Geary B, Syed AA, Whetton A, Soran H, Donn RP, Heald AH. Relationship between the Plasma Proteome and Changes in Inflammatory Markers after Bariatric Surgery. Cells 2021; 10(10),2798-2806.

Iqbal Z, Fachim HA, Gibson JM, Baricevic-Jones I, Campbell AE, Geary B, Donn RP, Hamarashid D, Syed A, Whetton AD, Soran H, Heald AH. Changes in the Proteome Profile of People Achieving Remission of Type 2 Diabetes after Bariatric Surgery. J. Clin. Med. 2021;10(16),3659-3678.

Gibb A, Pirrie SJ, Linton K, Warbey V, Paterson K, Davies AJ, Collins GP, Menne T, McKay P, Fields PA, Miall FM, Nagy E, Wheatley K, Reed R, Baricevic-Jones I, Barrington S, Radford J. Results of a UK National Cancer Research Institute Phase II study of brentuximab vedotin using a response-adapted design in the first-line treatment of patients with classical Hodgkin lymphoma unsuitable for chemotherapy due to age, frailty or comorbidity (BREVITY). Br. J. Haematol 2021; 193(1),63-71.


Pantoa T, Baricevic-Jones I, Suwannaporn P, Kadowaki M, Kubota M, Roytraku S, Mills ENC. Young rice protein as a new source of low allergenic plant-base protein. J. Cereal. Science 2020;93:102970.

McGurk KA, Dagliati A, Chiasserini D, Lee D, Plant D, Baricevic-Jones I, Kelsall J, Eineman R, Reed R, Geary B, Unwin RD, Nicolaou A, Keavney BD, Barton A, Whetton AD & Geifman N (2020) The use of missing values in proteomic data-independent acquisition mass spectrometry to enable disease activity discrimination. Bioinformatics 2020;36(7),2217-2223.

Rao H, Baricevic I, Bernard H, Smith F, Sayers R, Balasundaram A, Costello CA, Padfield P, Semic-Jusufagic A, Simpson A, Adel-Patient K, Xue W, Mills ENC. The Effect of the Food Matrix on the In Vitro Bio-Accessibility and IgE Reactivity of Peanut Allergens. Mol Nutr Food Res 2020; 64 (14): e1901093.


McDonald S, Reed R, Baricevic-Jones I; Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate, Ling S, Plant D, Barton A. Can serum interleukin-17 and interleukin-10 levels predict response to biologic treatments in patients with rheumatoid arthritis? Rheumatology (Oxford). 2019 Oct 1;58(10):1872-1873.


Nitride C, Lee V, Baricevic-Jones I, Adel-Patient K, Baumgartner S, Mills ENC. Integrating Allergen Analysis Within a Risk Assessment Framework: Approaches to Development of Targeted Mass Spectrometry Methods for Allergen Detection and Quantification in the iFAAM Project. J. AOAC Int. 2018 Jan 1;101(1):83-90.


 Patent 1 – Kit for allergy diagnosis

Scope – Chocolate challenge meal for diagnosis of food allergy.

Authors: Carol Ann Costello, Anuradha Balasundaram, Ivona Baricevic-Jones and Clare Mills.

This patent was awarded in the following countries: United Kingdom, France, Spain, Germany, Belgium, Austria, Greece, Ireland, Italy, Netherlands, Poland, Portugal, Norway, Switzerland, Sweden, Turkey, USA, Canada, Australia and Hong Kong.

Patent 2 – Oral food challenge meal formulation.

Scope – Chocolate challenge meal formula for blinding of high levels of peanut.

Authors: Clare Mills, Anuradha Balasundaram, Carol Ann Costello, Ivona Baricevic-Jones, Martin Wickham.

This patent is awarded in the USA (US patent number 11,439,342, publish date of 13 September 2022). Applications filled in for Canada, EU, Hong Kong, South Korea and Australia.


Skip to content